**Psychological Medicine**

**Disorder-specific and shared neurophysiological impairments of attention and inhibition in women with ADHD and women with bipolar disorder**

---Manuscript Draft---

<table>
<thead>
<tr>
<th>Manuscript Number:</th>
<th>PSM-D-15-00187R1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full Title:</td>
<td>Disorder-specific and shared neurophysiological impairments of attention and inhibition in women with ADHD and women with bipolar disorder</td>
</tr>
<tr>
<td>Article Type:</td>
<td>Original Article</td>
</tr>
</tbody>
</table>
| Corresponding Author: | Giorgia Michelini, MSc  
|                    | King's College London  
|                    | London, UNITED KINGDOM |
| Corresponding Author Secondary Information: | |
| Corresponding Author's Institution: | King's College London |
| Corresponding Author's Secondary Institution: | |
| First Author:     | Giorgia Michelini, MSc |
| First Author Secondary Information: | |
| Order of Authors: | Giorgia Michelini, MSc  
|                    | Glenn L. Kintsune, PhD  
|                    | Georgina M. Hosang, PhD  
|                    | Philip Asherson, MRC Psych, PhD  
|                    | Gráinne McLoughlin, PhD  
|                    | Jonna Kuntsi, PhD |
| Order of Authors Secondary Information: | |
| Manuscript Region of Origin: | UNITED KINGDOM |
| Abstract:          | Background: In adults, attention-deficit/hyperactivity disorder (ADHD) and bipolar disorder (BD) have certain overlapping symptoms, which can lead to uncertainty regarding the boundaries of the two disorders. Despite evidence of cognitive impairments in both disorders separately, such as in attentional and inhibitory processes, data on direct comparisons across ADHD and BD on cognitive-neurophysiological measures are as yet limited. Methods: We directly compared cognitive performance and event-related potential (ERP) measures from a Cued Continuous Performance Test (CPT-OX) in 20 women with ADHD, 20 women with BD (currently euthymic) and 20 control women. Results: The NoGo-N2 was attenuated in women with BD, reflecting reduced conflict monitoring, compared to women with ADHD and controls (both p<0.05). Both ADHD and BD groups showed a reduced NoGo-P3, reflecting inhibitory control, compared to controls (both p<0.05). In addition, the CNV was significantly reduced in the ADHD group (p=0.05), with a trend in the BD group (p=0.07), compared to controls. Conclusions: These findings indicate potential disorder-specific (conflict monitoring) and overlapping (inhibitory control, and potentially response preparation) neurophysiological impairments in women with ADHD and women with BD. The identified neurophysiological parameters further our understanding of neurophysiological impairments in women with ADHD and BD, and are candidate biomarkers that may aid in the identification of the diagnostic boundaries of the two disorders. |
Disorder-specific and shared neurophysiological impairments of attention and inhibition in women with ADHD and women with bipolar disorder

Giorgia Michelini¹, M.Sc.; Glenn L. Kitsune¹², Ph.D.; Georgina M. Hosang²³, Ph.D.; Philip Asherson¹, M.R.C. Psych., Ph.D.; Gráinne McLoughlin¹, Ph.D.; Jonna Kuntsi¹*, PhD.

¹King’s College London, MRC Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, London, UK

²King’s College London, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, London, UK

³Department of Psychology, Goldsmiths, University of London, London, UK

*Correspondence to Jonna Kuntsi, MRC Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, De Crespigny Park, London SE5 8AF, UK. Email: jonna.kuntsi@kcl.ac.uk.
ABSTRACT

Background: In adults, attention-deficit/hyperactivity disorder (ADHD) and bipolar disorder (BD) have certain overlapping symptoms, which can lead to uncertainty regarding the boundaries of the two disorders. Despite evidence of cognitive impairments in both disorders separately, such as in attentional and inhibitory processes, data on direct comparisons across ADHD and BD on cognitive-neurophysiological measures are as yet limited. Methods: We directly compared cognitive performance and event-related potential (ERP) measures from a Cued Continuous Performance Test (CPT-OX) in 20 women with ADHD, 20 women with BD (currently euthymic) and 20 control women. Results: The NoGo-N2 was attenuated in women with BD, reflecting reduced conflict monitoring, compared to women with ADHD and controls (both p<0.05). Both ADHD and BD groups showed a reduced NoGo-P3, reflecting inhibitory control, compared to controls (both p<0.05). In addition, the CNV was significantly reduced in the ADHD group (p=0.05), with a trend in the BD group (p=0.07), compared to controls. Conclusions: These findings indicate potential disorder-specific (conflict monitoring) and overlapping (inhibitory control, and potentially response preparation) neurophysiological impairments in women with ADHD and women with BD. The identified neurophysiological parameters further our understanding of neurophysiological impairments in women with ADHD and BD, and are candidate biomarkers that may aid in the identification of the diagnostic boundaries of the two disorders.

Keywords: ADHD; bipolar disorder; event-related potentials; attention; inhibitory control; conflict monitoring.
INTRODUCTION

Attention-deficit/hyperactivity disorder (ADHD) and bipolar disorder (BD) are common psychiatric conditions in adults, affecting around 2-4% and 1-2% of the adult population, respectively (Merikangas et al. 2011; Willcutt, 2012). Although ADHD and BD represent distinct conditions, their diagnostic formulations present certain areas of symptomatic overlap. In adults, ADHD may be manifest with some symptoms common to mania/hypomania, such as distractibility, psychomotor restlessness and talkativeness (Skirrow et al. 2012a; Asherson et al. 2014). Additionally, both disorders are associated with features of mood dysregulation, such as irritability and emotional lability (Skirrow et al. 2012a; Skirrow et al. 2014; Kitsune et al. submitted under review). Of note, ADHD symptoms are chronic and trait-like, while BD symptoms of mania and depression tend to occur for a distinct period of time (Asherson et al. 2014). Yet, individuals with BD may still show residual symptoms of distractibility and mood dysregulation (overlapping with ADHD), and residual cognitive and functional impairments between episodes (Torres et al. 2007; Henry et al. 2013). Importantly, symptomatic similarities can result in uncertainty regarding the boundaries of the two disorders, and difficulties in distinguishing between the two disorders in some patients, which in turn may result in inappropriate treatment decisions (Asherson et al. 2014).

Adults with ADHD or BD may display similar cognitive impairments. For example, both ADHD and euthymic BD are associated with poor accuracy in attentional and inhibitory processing tasks (Robinson et al. 2006; McLoughlin et al. 2010; Torralva et al. 2011) and increased reaction time variability (RTV), which may reflect short-term fluctuations in attentional performance (Brotman et al. 2009; Kuntsi et al. 2010; Kuntsi & Klein, 2012). Comparative
studies across ADHD and BD, using identical measures, may aid in the identification of attentional and inhibitory deficits underlying overlapping symptoms and functional impairment, yet empirical data are currently limited.

The investigation of neurophysiological processes with event-related potentials (ERPs) provides a direct measure of covert brain activity underlying behavioural performance with millisecond temporal resolution, and may enable a sensitive comparison of cognitive profiles in ADHD and BD (Banaschewski & Brandeis, 2007; McLoughlin et al. 2014a). Several previous studies on attentional and inhibitory processing in ADHD have explored ERPs during the Cued Continuous Performance Test (CPT-OX), which involves presentation of Cue, target (Go) and non-target (NoGo) stimuli and requires a response only when a target follows a Cue (van Leeuwen et al. 1998; Banaschewski et al. 2004). A reduced fronto-central P3 has consistently been reported in response to NoGo stimuli (NoGo-P3) in children, adolescents and adults with ADHD compared to controls, reflecting abnormal inhibitory control (Valko et al. 2009; Doehnert et al. 2010; McLoughlin et al. 2010, 2011; Albrecht et al. 2013; Tye et al. 2014). Attenuations in a parietal P3 after presentation of Cue stimuli (Cue-P3) and in the subsequent contingent negative variation (CNV), a late negative potential before the occurrence of the next stimulus, have also been found in individuals with ADHD, reflecting impaired attentional orienting and response preparation, respectively (Albrecht et al. 2013; Doehnert et al. 2010; McLoughlin et al. 2010, 2011), although case-control differences in these components have not been reported in all studies (Dhar et al. 2010; Skirrow et al. 2012b). Differences between adults with ADHD and control adults are generally not found in other ERP components elicited by this task; such as the P3 in response to target (Go-P3), reflecting response execution, and the N2 to non-target stimuli
(NoGo-N2), indexing conflict monitoring, which refers to the ability to monitor ongoing behaviour, detect conflict and adjust response selection (McLoughlin et al. 2010; Yeung & Cohen, 2006). N2 deflections are particularly elicited by high-conflict trials, such as non-target or incongruent stimuli, and are attenuated in ADHD individuals in paradigms inducing higher conflict-monitoring demands than the CPT-OX, such as flanker tasks, suggesting possible modulations of this component by task and stimuli (Barry et al. 2009; McLoughlin et al. 2009, 2014).

In ERP studies, BD has been associated with attenuations in early sensory and attentional ERP components (e.g., mismatch negativity (MMN), P50 and P2) in auditory tasks (Hall et al. 2007; Jahshan et al. 2012; Cabranes et al. 2013, Swann et al. 2013). Reduced P3 enhancements to target stimuli have been reported in adults with BD in studies using a visual paradigm with standard, deviant and target conditions (Maekawa et al. 2013) and using an oddball paradigm (Hall et al. 2007), but not in all studies (Schulze et al. 2008; Bestelmeyer, 2012). Some evidence also indicates impairments in conflict monitoring in adults with BD, indexed by reduced N2 in response to target stimuli with an auditory oddball task (Ethridge et al. 2012) and reduced error-related negativity (ERN) in error responses (Morsel et al. 2014). Despite initial evidence that may suggest impairments in ERPs of attentional and inhibitory processing in BD, however, ERP data on these processes is limited, and no studies, to our knowledge, have used the CPT-OX.

Direct comparisons on cognitive performance and ERP measures in ADHD and BD are sparse. One study on adults with ADHD and adults with BD investigating ERP measures of reward processing found significant differences in the amplitude of a reward-sensitive P3,
which was attenuated in ADHD but enhanced in BD participants compared to controls (Ibanez et al. 2012). However, no study to date has compared ERP components associated with attentional and inhibitory processing in both disorders using the CPT-OX. In addition, most studies of this kind, especially on ADHD, have used male samples because, among children, ADHD is more prevalent in males than in females, and very little is known about these processes in females. Yet, a similar prevalence of ADHD has been reported in both adult men and women (Faraone & Biederman, 2005; Das et al. 2012). Similarly, comparable gender ratios have been found for BD in adults (Pini et al. 2005).

The aim of the current study was to directly compare cognitive performance and ERP measures associated with attentional and inhibitory processing in ADHD and BD in adults. This study was conducted on an all-female sample, in order to match the groups on gender but also to explore the neglected area of ERP indices associated with these processes in females. Based on previous studies of male participants (McLoughlin et al. 2010; Albrecht et al. 2013; Doehnert et al. 2013), we predicted that women with ADHD would show reduced NoGo-P3, Cue-P3 and CNV, but normal NoGo-N2. Given the limited and mixed results in ERP studies of BD individuals and the lack of similar studies using the CPT-OX, we adopted an exploratory approach for the BD group and for the comparison with ADHD.

METHODS

Sample

The sample for this study consisted of 60 adult women between 20-52 years, divided into three groups: 20 with ADHD, 20 with BD and 20 controls. Participants with ADHD were
recruited from the National Adult ADHD Clinic at the Maudsley Hospital, where any female cases meeting inclusion criteria were considered for potential inclusion in the study. Participants with BD were recruited from the Maudsley Psychosis Clinic and a sample that had previously participated in another research study (Hosang et al. 2012). Control participants were recruited from the Mindsearch volunteer database maintained by the Institute of Psychiatry, King’s College London, which comprises of several thousand potential participants. Participants were randomly selected from all those meeting recruitment criteria for this study.

Diagnosis in the clinical groups was confirmed by checking medical records for details of diagnosis and psychiatric history from medical records, following DSM-IV criteria (APA, 2000). All of the ADHD participants had a current combined-type diagnosis or a current inattentive-type diagnosis with sufficient symptoms of hyperactivity-impulsivity in childhood to meet a childhood combined-type diagnosis. Participants in the BD group had a diagnosis of BD Type I, having experienced at least one manic episode in the past. Those who were experiencing a manic episode at the time of the assessment were excluded; all participants included in the BD group manic episodes, but were currently euthymic. Exclusion criteria for all groups were drug or alcohol dependency in the last 6 months, autism, epilepsy, neurological disorders, brain injury, past ECT treatment, current involvement in another research trial likely to alter symptom severity, pregnancy or a limited proficiency in English language. Those Individuals with ADHD and individuals with BD with a reported comorbidity of both ADHD and BD or who were currently experiencing a manic episode were also excluded. Control participants, who reported a history of psychiatric disorders or who were taking psychiatric medication, were excluded from the study. Comorbidity in the clinical
groups and lack of psychiatric disorders in the control group were further assessed through clinical evaluations when participants underwent the cognitive-EEG assessment for this study. Further details on the clinical assessment of this sample can be found elsewhere (Kitsune et al. under review). In brief, ADHD was excluded in the BD group after conducting the Diagnostic Interview for Adult ADHD (DIVA v. 2.0; Kooij & Francken, 2007). BD was excluded in the ADHD group by checking for a history of past episodes of depression or hypomania/mania and evaluating current mood symptoms using the Altman Self-Rating Mania Scale (Altman et al. 1997) and the Becks Depression Inventory (Beck et al. 1996), and current and lifetime ever symptoms using the Young Mania Rating Scale (Young et al. 1978). The ADHD and BD groups did not differ significantly on any of the mood scales for current symptoms (Kitsune et al. under review).

All participants had normal or corrected-to-normal vision. Mean age did not differ by group [F(2, 59)=1.63, p=0.21], with a mean age of 37.40 (SD=7.70) for the ADHD group, 40.30 (SD=7.70) for the BD group and 36.7 (SD=4.30) for the control group. Participants’ IQs were assessed with the Wechsler Abbreviated Scale of Intelligence Fourth Edition (WASI-IV; Wechsler, 1999) and did not differ between groups [F(2, 58)=1.37, p=0.26], with mean IQs of 104 (SD=17.90) for ADHD, 108 (SD=12.50) for BD and 112 (SD=14.20) for control participants. Participants with ADHD were asked to stop taking any stimulant medication prescribed for their ADHD 48 hours prior to the assessment. For ethical reasons, participants were not asked to stop taking mood stabilisers (70% of the BD group), anti-psychotic medication (40% of the BD group) or anti-depressants (7% of the ADHD group and 25% of the BD group) they had been prescribed. All participants were asked to refrain from caffeinated drinks and nicotine two hours prior to the testing session. Ethical approval for
the study was granted by the Camberwell St Giles Research Ethics Committee (approval number 11/LO/0438) and all participants provided informed consent.

**Procedure and cognitive performance measures**

Participants attended a single 4.5 hour research session (including breaks) for cognitive-EEG assessment, IQ assessment and clinical interviews. The task was a CPT-OX, flanker version (Doehnert et al. 2008; McLoughlin et al. 2010, 2011). This is a cued-Go/NoGo task that probes attention, preparation and response inhibition or control. The task consists of 400 letter arrays formed of a centre letter with incompatible flankers on each side to increase difficulty for adults. Each letter array was presented for 150 ms with a SOA (stimulus onset asynchrony) of 1.65 s in a pseudo-randomised order at the centre of a computer monitor. The tasks involves the presentation of 80 Cues (XOX) followed either by 40 Go (OXO) and 40 NoGo (XDX) stimuli, alternated with random letter sequences as distractors. Participants were instructed to respond only to Cue-Go sequences by pressing a button as quickly as possible with the digit finger of their preferred hand, and to withhold the response in presence of a NoGo stimulus, of a Go not preceded by a Cue (40 trials), or of any other irrelevant letters. The task was practiced prior to task performance and. The task lasted 11 minutes. The task, followed a 2 x 3 minute resting state recordings, and was run as first in a battery of three cognitive-EEG tasks.

Cognitive performance measures included target mean reaction time (MRT, i.e. mean latency of responding in milliseconds after target onset), RTV (measured as SD of target reaction time) and number of errors. MRT and RTV were calculated across correctly answered Go trials. Errors included omission errors (non-response to Go trials), total
commission errors (response to Cue, NoGo or distractor stimuli) and OXO-not-XOX commission errors (response to a Go not following a Cue).

**Electrophysiological recording and analysis**

The EEG was recorded from a 62 channel DC-coupled recording system (extended 10–20 montage), using a 500 Hz sampling-rate, impedances under 10 kΩ, and FCz as the recording reference. The electro-oculograms (EOGs) were recorded from electrodes above and below the left eye and at the outer canthi. The EEG data were analysed using Brain Vision Analyzer 2.0 (Brain Products, Germany). Researchers were blind to group status during EEG pre-processing and analysis. Raw EEG recordings were down-sampled to 256 Hz, re-referenced to the average of all electrodes, and digitally filtered using Butterworth band-pass filters (0.1-30 Hz, 24 dB/oct). All trials were also visually inspected for electrical artefacts (due to electrical noise in the EEG recording) or obvious movement, and sections of data containing artefacts were removed manually. Ocular artefacts, corresponding to blink-related and vertical and horizontal eye movements, were identified using the infomax Independent Component Analysis algorithm (ICA; Jung et al. 2000), which allows for removal of the components associated with ocular artefacts by back-projection of all but those components. Sections of data with remaining artefacts exceeding ± 100 μV in any channel or with a voltage step greater than 50 μV were automatically rejected. Baseline correction was performed using a 500-ms prestimulus reference period.†

†Since most previous ERP analyses on CPT-OX did not apply a baseline subtraction (Banaschewski et al. 2004; McLoughlin et al. 2010, 2011; Albrecht et al. 2013; Doehnert et al. 2013), analyses were also repeated without baseline correction. Results of data without baseline correction were comparable for the NoGo-N2, NoGo-P3 and Go-P3, but partly changed for the Cue-P3 and CNV (see Supplementary material).
Stimulus-locked epochs (stimulus window from −200 to 1650 ms) were averaged based on three different response conditions: Cue, Go and NoGo. Averages only included trials with correct responses (Go) or correctly rejected trials (NoGo and Cue) and contained at least 20 artefact-free segments (see Supplementary material for number of segments included in the ERP average by group). ERP measures were identified within the selected electrodes and latency windows for which effects were expected to be largest, based on previous studies (McLoughlin et al. 2010, 2011; Albrecht et al. 2013; Doehnert et al. 2013) and verified against the topographic maps and the grand averages (Fig. 1-3). ERPs were measured as the mean amplitude in the designated latency window. This approach has been adopted in previous similar studies (Groom et al. 2010; Tye et al. 2014), and has the advantage of being unaffected by latency variability (Luck, 2005). In Cue trials, the P3 was measured at Pz between 300-650 ms, and the CNV at Cz between 1300-1650 ms. In NoGo trials, the N2 was measured at Fz between 175-3252 ms, and the P3 at Cz between 250-550 ms. In Go trials, the P3 was measured at CPz between 250-500 ms. A clear N2 was not observed in Go trials, in line with other studies on tasks inducing a low-conflict-monitoring demand (Bokura et al. 2001; Gajewski & Falkenstein, 2013) and was not included into the analysis.

**Statistical analyses**

All participants were included in the analysis of cognitive performance data. Two ADHD participants were excluded from the ERP analysis of the Go condition due to having less than 20 artefact-free segments available for analysis.
Group differences on the reaction time measures were explored using univariate ANOVAs, followed by post-hoc t-tests. MRT and RTV had skewed distributions and were log-transformed with optimised minimal skew through the ‘Inskew0’ command in Stata (Stata Corp, College Station, Texas). Performance accuracy was generally high as errors were rare, in line previous studies on this task (McLoughlin et al. 2010, 2011; Albrecht et al. 2013; Doehnert et al. 2013). Since distribution of errors was thus not normal and no transformations were successful, effects of group on these variables were entered into non-parametric analysis, using Kruskal-Wallis tests, followed by post-hoc Mann-Whitney U tests.

Group effects on ERP parameters were tested with separate ANOVAs, followed by post-hoc t-tests. All ERP measures had normal distribution. We report both p-values (p<0.05 for significance and p<0.10 for a trend) and effect sizes (Cohen’s d) for comparisons of cognitive performance and ERP measures. Effect sizes were calculated using the difference in the means, divided by the pooled standard deviation, where d=0.20 constitutes a small effect, d=0.50 a medium effect and d=0.80 a large effect (Cohen, 1988).

RESULTS

Cognitive performance measures

A trend-level effect of group emerged for RTV [F(2,57)=2.67, p=0.08]. Post-hoc analyses revealed a significant difference between BD and control groups (p=0.03) and a trend-level difference between ADHD and control groups (p=0.06) on RTV, both with medium effect sizes (Table 1), but no differences between ADHD and BD groups (p=0.93). Groups did not differ on MRT [F(2,57)=1.47, p=0.24].
Trend-level effects emerged on the number of total commission errors \( [H(2)=4.96, p=0.08] \) and omission errors \( [H(2)=4.74, p=0.09] \). Post-hoc analyses indicated that participants with ADHD made significantly more commission \( (p=0.03) \) and omission \( (p=0.04) \) errors than controls, with medium and small effect sizes, respectively (Table 1). Participants with BD showed a trend-level difference on the number of omission errors \( (p=0.07) \) from controls, with a small effect size, but no difference on commission errors \( (p=0.34) \). ADHD and BD groups did not differ on commission \( (p=0.20) \) or omission \( (p=0.90) \) errors. No effect of group emerged for OXO-not-XOX commission errors \( [H(2)=3.81, p=0.15] \).

[Table 1 about here]

**ERP parameters**

* Cue condition

An effect of group did not emerge on the Cue-P3 \( [F(2,57)=1.31, p=0.28] \).

A trend-level effect of group emerged for the CNV \( [F(2,57)=2.86, p=0.07] \). Post-hoc comparisons showed a significant difference between the ADHD and the control group \( (p=0.05) \) and a trend-level difference between the BD and the control groups \( (p=0.09) \), both with medium effect size (Table 1). No difference emerged between the two clinical groups \( (p=0.85) \).

[Figure 1 about here]
NoGo condition

A significant effect of group on the NoGo-N2 [F(2,57)=4.03, p=0.02]. Post-hoc analyses revealed that the BD group significantly differed from ADHD (p=0.015) and control (p=0.04) groups, with large and medium effect size, respectively (Table 1). ADHD and control groups did not differ from each other (p=0.66).

[Figure 2 about here]

A significant effect of group emerged on the NoGo-P3 [F(2,57)=3.86, p=0.03]. Post-hoc analyses showed that both ADHD (p=0.01) and BD (p=0.03) groups significantly differed from controls, respectively with large and medium effect sizes (Table 1), but not from each other (p=0.88).

[Figure 3 about here]

Go condition

No significant effect of group emerged on the Go-P3 [F(2,55)=0.73, p=0.49].

DISCUSSION

In a direct comparison of women with ADHD, women with BD and control women on cognitive performance and ERP measures from a CPT-OX task, we report evidence for both disorder-specific (conflict monitoring) and overlapping (inhibitory control and potentially
response preparation) neurophysiological impairments across the disorders. The current study represents the first cognitive-electrophysiological investigation comparing attentional and inhibitory processing in adults with ADHD and adults with BD. In addition, since the majority of previous ERP studies on ADHD have used male samples (McLoughlin et al. 2010, 2011; Albrecht et al. 2013; Doehnert et al. 2013), and very few studies of this kind have been conducted in BD, our all-female sample furthers our understanding of neurophysiological impairments in females with either of these disorders.

Our ERP results show a significant difference between the ADHD and BD groups in the amplitude of the N2 in response to NoGo stimuli, which was reduced in participants with BD compared to the other two groups. The N2 is considered to reflect conflict-monitoring processing (Holroyd et al. 2003; Yeung & Cohen, 2006) and to depend on the amount of correct response processing needed to overcome a conflicting response. In the CPT-OX, this process may be represented by the bias towards the response after a Cue, which requires the preparation of a response, and produces increased conflict monitoring when the prepared response has to be stopped in presence of a non-target. The reduced N2 in women with BD aligns with previous evidence of attenuated N2 elicited with an oddball task (Ethridge et al. 2012) and of a reduced ERN in error responses (Morsel et al. 2014). Both N2 and ERN in conditions inducing conflict, such as in non-target or incongruent trials, are thought to reflect conflict monitoring (Yeung & Cohen, 2006). Our results may therefore indicate that women with BD show impaired conflict monitoring compared to women with ADHD and control women. In line with previous studies using the CPT-OX (McLoughlin et al. 2010, 2011; Albrecht et al. 2013; Doehnert et al. 2013), we did not find an attenuated
NoGo-N2 in women with ADHD, although reduced N2 have been associated with ADHD in tasks inducing higher conflict demands (McLoughlin et al. 2009, 2014b).

We also identified abnormalities in ERPs that distinguished women in both clinical groups from controls, indicating shared neurophysiological impairments across ADHD and BD. The reduced P3 in response to NoGo stimuli in both ADHD and BD groups, compared to the control group, suggests a similar pattern of impaired response inhibition to that previously reported in investigations of children and adults with ADHD (McLoughlin et al. 2010, 2011; Albrecht et al. 2013; Doehnert et al. 2013). The reduced NoGo-P3 in women with BD also aligns with previous cognitive research finding deficits in inhibitory control in euthymic BD (Robinson et al. 2006; Robinson et al. 2013). These attenuations of the NoGo-P3 in both disorders therefore likely represent an area of overlapping impairment in brain processes implicated in the inhibition of incorrect response. Yet, this inhibitory control deficit in women with BD was temporally preceded by other processing deficits in the NoGo-N2. As such, in ERPs to non-targets, while women with ADHD seem primarily impaired in response inhibition, women with BD show a broader deficit in both conflict monitoring and inhibitory control.

Additionally, we report an attenuation in the CNV in women with ADHD compared to controls, and also potentially in women with BD (trend-level difference), both with a medium effect size. These results replicate previous studies reporting reduced CNV in individuals with ADHD (McLoughlin et al. 2010, 2011; Albrecht et al. 2013; Doehnert et al. 2013; Tye et al. 2014), and suggest another potential area of shared impairment with BD. However, we note that the comparison between BD and control participants was only at
trend level. If replicated also in BD, this attenuation of the CNV would index an overlapping impairment in response preparation in the two disorders.

The lack of a difference between women with ADHD and controls in the Cue-P3 is inconsistent with some previous investigations showing a reduced Cue-P3 in ADHD samples (McLoughlin et al. 2010; Albrecht et al. 2013). Yet, these attenuations have not been reported in all studies (Dhar et al. 2010; Skirrow et al. 2012b) and the difference in the Cue-P3 emerged as significant, but with a small effect size, in a recent larger-scale study of adolescents and young adults with ADHD (Cheung et al. in press 2015). In the present study, the normal Cue-P3 in ADHD may be due to an effect of gender, the current study being the first using an all-female sample. An age-effect is also plausible, since this study included adults of a slightly older and broader age-range compared to previous investigations (e.g., McLoughlin et al. 2010) and developmental changes have been reported for the Cue-P3, suggesting that ADHD-control differences may decline with age (Doehnert et al. 2013). Further studies on larger samples that include participants of both genders and a broader age range are needed to clarify potential gender- and age-effects on these processes in ADHD.

While ERP measures of conflict monitoring differentiated the ADHD and BD groups, cognitive performance data did not suggest differences between the two clinical groups. Our cognitive performance results potentially suggest poorer performance and higher RTV in both ADHD and BD groups, compared to controls, consistent with previous studies reporting lower accuracy and higher RTV in ADHD and BD independently (Brotman et al. 2009; Kuntsi et al. 2010; Torralva et al. 2011). This pattern of results, with differences
between ADHD and BD groups observed in the neurophysiological markers but not at the cognitive performance level, may reflect greater specificity of the neurophysiological markers in detecting differences between clinical groups.

The following limitations of this study should be taken into account when interpreting these data. Firstly, although the groups were matched on gender, age and IQ, there were differences in the prescribed medications that participants with ADHD or BD were taking. While we asked participants with ADHD to stop taking stimulant medications 48 hours prior to the assessment, it was not possible, for ethical reasons, to ask participants to stop mood-stabilising, anti-psychotic or antidepressant medications. Given limited numbers in medication sub-groups, we were not able to directly test the effect of medication on ERP measures which represents a limitation of the current study. The effects of medication are difficult to control for in cross-disorder comparison studies where different treatments may be prescribed to different groups of psychiatric patients. Although the understanding of the effects of medications on ERPs is still limited, previous studies suggest that medications may normalise ERPs measures (Anderer et al. 2002; Karaaslan et al. 2003; Galletly et al. 2005). As such, in this study, a medication effect could potentially have resulted in ERPs comparable to controls. Yet, both clinical groups, although some participants were medicated, showed reduced ERP measures compared to controls. Therefore, although the effect of medication represents a potential confounder of this study and may have attenuated some case-control differences, we report impairments in both clinical groups which may not have been produced by the effect of medication. Future studies on samples including non-medicated individuals or a higher number of individuals in each medication sub-group are needed to clarify whether our results were—may have been affected by medication effects. A second
limitation is that, by using an area measure, we were not able to obtain latency data. This approach, previously adopted in similar ERP studies (Groom et al. 2010; Tye et al. 2014), was preferred for having the advantage, over peak measures, of being unaffected by latency variability and of providing a reliable measure of amplitude even when the identification of clear peaks is not possible for all subjects (Luck, 2005). Although some previous studies found prolonged latency of ERP components in BD (Chun et al. 2013; Maekawa et al. 2013), our ERP grand averages did not suggest latency differences, thus our area measure likely captured most of the differences between the groups on ERP measures. Finally, in order to increase homogeneity of the sample, this investigation was conducted on an all-female sample, with slightly higher than expected IQ in the clinical groups. Replication in future investigations with bigger samples of both genders and including individuals with a wider range of IQs is required in order to generalise these findings to more typical clinical populations.

In conclusion, our results represent some of the first evidence of disorder-specific and shared impairments in brain processes involved in attentional orienting, conflict monitoring and inhibitory control in women with ADHD and BD, with moderate-to-large effect sizes. This investigation of neurophysiological processes furthers our understanding of impairments associated with ADHD and BD, and the identification of objective measures showing differences between ADHD and BD may assist in differentiating between the two disorders when their distinction is not clear at clinical consultations. If replicated in larger-scale studies, the neurophysiological biomarkers of distinct patterns in brain activity may aid in the identification of the diagnostic boundaries of ADHD and BD in adults. More broadly, given that ADHD and BD are both highly heritable disorders, the identified
neurophysiological indices may represent intermediate phenotypes between diagnosis and genetic factors influencing a disorder, as suggested by genetic and family studies on ERP indices of attentional and inhibitory processing showing shared familial/genetic influences with ADHD (McLoughlin et al. 2011; Albrecht et al. 2013; Albrecht et al. 2014). Future studies can investigate causal models of ADHD and BD, by exploring to what extent overlapping and disorder-specific impairments in brain function are accounted for by specific or shared genetic influences on the two disorders and, in turn, further our understanding on the pathways to distinct and overlapping features in ADHD and BD.

Acknowledgements

We thank all who make this research possible: The National Adult ADHD Clinic at the South London and Maudsley Hospital, Dr. Helen Costello, Prof. Sophia Frangou, Prof. Anne Farmer, Jessica Deadman, Hannah Collyer, Sarah-Jane Gregori, and all participants who contributed their time to the study.

Financial support

Giorgia Michelini is supported by a 1+3 PhD studentship awarded by the MRC Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College London (G9817803). This project was supported by an Economic and Social Research Council studentship to Dr. Glenn L. Kitsune (ES/100971X/1).

This paper represents independent research part funded by the National Institute for Health Research (NIHR) Biomedical Research Centre and Dementia Unit at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.
Conflict of Interest

Philip Asherson has received funding for research by Vifor Pharma, and has given sponsored talks and been an advisor for Shire, Janssen–Cilag, Eli-Lilly, Flynn Pharma and Pfizer, regarding the diagnosis and treatment of ADHD. All funds are received by King’s College London and used for studies of ADHD. The other authors report no conflicts of interest.

Ethical standards

The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.
REFERENCES


**Table 1** Cognitive performance and ERP measures from the CPT-OX: means (SDs), effect sizes (Cohen’s d) and significance of group comparisons.

<table>
<thead>
<tr>
<th></th>
<th>ADHD (n=20)*</th>
<th>BD (n=20)</th>
<th>Controls (n=20)</th>
<th>ADHD vs. BD</th>
<th>ADHD vs. Controls</th>
<th>BD vs. Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>mean (SD)</td>
<td>mean (SD)</td>
<td>mean (SD)</td>
<td>effect size (d)</td>
<td>effect size (d)</td>
<td>effect size (d)</td>
</tr>
<tr>
<td>MRT</td>
<td>425.31 (75.74)</td>
<td>418.30 (67.41)</td>
<td>391.58 (63.68)</td>
<td>0.05</td>
<td>0.49</td>
<td>0.44</td>
</tr>
<tr>
<td>RTV</td>
<td>109.18 (58.83)</td>
<td>101.73 (37.77)</td>
<td>76.91 (39.24)</td>
<td>0.02</td>
<td>0.60†</td>
<td>0.68*</td>
</tr>
<tr>
<td>OE</td>
<td>1.10 (1.55)</td>
<td>1.35 (2.52)</td>
<td>0.60 (1.57)</td>
<td>0.12</td>
<td>0.32*</td>
<td>0.36†</td>
</tr>
<tr>
<td>OXO-not-XOX CE</td>
<td>1.05 (1.88)</td>
<td>0.60 (2.04)</td>
<td>0.50 (0.89)</td>
<td>0.23</td>
<td>0.37</td>
<td>0.06</td>
</tr>
<tr>
<td>Total CE</td>
<td>7.25 (16.03)</td>
<td>2.40 (5.39)</td>
<td>0.75 (0.97)</td>
<td>0.41</td>
<td>0.57*</td>
<td>0.43</td>
</tr>
<tr>
<td>Cue-P3 at Pz</td>
<td>2.30 (1.64)</td>
<td>1.36 (1.80)</td>
<td>1.83 (2.04)</td>
<td>0.56</td>
<td>0.26</td>
<td>0.25</td>
</tr>
<tr>
<td>CNV at Cz</td>
<td>-2.24 (1.03)</td>
<td>-2.31 (1.36)</td>
<td>-3.31 (2.12)</td>
<td>0.06</td>
<td>0.66*</td>
<td>0.58†</td>
</tr>
<tr>
<td>NoGo-N2 at Fz</td>
<td>0.57 (1.88)</td>
<td>2.41 (2.64)</td>
<td>0.84 (2.07)</td>
<td><strong>0.83</strong></td>
<td>0.14</td>
<td>0.68*</td>
</tr>
<tr>
<td>NoGo-P3 at Cz</td>
<td>5.42 (2.73)</td>
<td>5.56 (3.31)</td>
<td>7.68 (2.57)</td>
<td>0.05</td>
<td><strong>0.88</strong></td>
<td>0.73*</td>
</tr>
<tr>
<td>Go-P3 at CPz</td>
<td>5.01 (2.76)</td>
<td>5.56 (3.23)</td>
<td>6.10 (2.18)</td>
<td>0.19</td>
<td>0.45</td>
<td>0.20</td>
</tr>
</tbody>
</table>

Note: mean and SD were calculated on raw data. Large effect sizes are given in bold, medium effect sizes are given in italics; *p<0.05, †p<0.10.

Abbreviations: ADHD, attention deficit hyperactivity disorder; BD, bipolar disorder; CE, commission errors; CNV, contingent negative variation; MRT, mean reaction time in milliseconds; RTV, within-subject variability in reaction times in milliseconds; OE, omission errors.

*Only 18 participants with ADHD were included in the average of the Go condition, as two participants did not have at least 20 artefact-free segments.
FIGURES

**Figure 1 (A)** Grand average event-related potentials (ERPs) to Cue stimuli at the Cz electrode, showing the CNV in the 1300-1650 ms window (ADHD, attention-deficit/hyperactivity disorder, shown in red; BD, bipolar disorder, in green; Controls, in black), and **(B)** topographic maps for each group.
Figure 2 (A) Grand average event-related potentials (ERPs) to NoGo stimuli at the Fz electrode, showing the NoGo-N2 in the 175-325 ms window (ADHD, attention-deficit/hyperactivity disorder, shown in red; BD, bipolar disorder, in green; Controls, in black), and (B) topographic maps for each group.
Figure 3 (A) Grand average event-related potentials (ERPs) to NoGo stimuli at the Cz electrode, showing the NoGo-P3 in the 250-550 ms window (ADHD, attention-deficit/hyperactivity disorder, shown in red; BD, bipolar disorder, in green; Controls, in black), and (B) topographic maps for each group.
Figure 1

Click here to download Figure(s): Fig1_18022015_PsychMedSub.tif
SUPPLEMENTARY MATERIAL

Number of artefact-free segments included in each condition

The average number of segments in each group for the Cue, NoGo and Go conditions is reported in Supplementary table 1. The number of segments was entered into univariate ANOVA to check for group differences, with ‘group’ as between-subjects variable (ADHD, BD and control participants). Groups did not differ on the number of artefact-free segments for the Cue condition \(F(2, 57)=0.30, p=0.75\), the NoGo condition \(F(2, 57)=0.15, p=0.87\) or Go condition \(F(2, 55)=0.49, p=0.62\).

Analysis of ERP parameters without baseline correction

The majority of previous ERP analyses on CPT-OX in ADHD samples did not apply a baseline subtraction (Banaschewski et al. 2004; McLoughlin et al. 2010, 2011; Albrecht et al. 2013; Doehnert et al. 2013). In this study, we chose to apply a baseline correction in order to reduce the influence of pre-stimulus activity on our ERP measures. However, analyses were also repeated without baseline correction in order to allow comparison with previous results.

Cue condition

A trend-level effect of group emerged for the Cue-P3 \(F(2,57)=2.48, p=0.09\). Post-hoc comparisons showed a significant difference between the ADHD and the BD group \(p=0.03\), with large effect size (Supplementary table 2). The control group did not differ from either the ADHD \(p=0.59\) or the BD \(0.14\) groups.
A significant effect of group emerged for the CNV \([F(2,57)=3.68, p=0.03]\). Post-hoc comparisons showed a significant difference between the ADHD and the control group \((p=0.01)\), with large effect size (Supplementary table 2). The BD group did not differ from either the ADHD \((p=0.22)\) or the control \((0.15)\) groups.

**NoGo condition**

A significant effect of group on the NoGo-N2 \([F(2,57)=5.12, p=0.01]\). Post-hoc analyses revealed that BD participants significantly differed from ADHD \((p=0.01)\) and control \((p=0.02)\) participants, both with large effect sizes (Supplementary table 2). The ADHD and the control groups did not differ from each other \((p=0.68)\).

A significant effect of group emerged on the NoGo-P3 \([F(2,57)=3.35, p=0.04]\). Post-hoc analyses showed that both ADHD \((p=0.05)\) and BD \((p=0.02)\) participants significantly differed from controls, respectively with medium and large effect sizes (Supplementary table 2), but not from each other \((p=0.55)\).

**Go condition**

No significant effect of group emerged on the Go-P3 \([F(2,55)=0.61, p=0.55]\).

**Comparison with results of data with baseline correction**

Results of data without baseline correction (Supplementary table 2) showed a reduced Cue-P3 in participants with BD compared to participants with ADHD, which was not observed in data with baseline correction. No difference emerged between the BD and control groups in
the CNV, which was at trend level in results of data with baseline correction. Group differences in ERPs from the NoGo and Go conditions remained the same.

Of note, an ADHD-control difference in the Cue-P3 was not found when analysing data with or without baseline correction. Although this difference has been reported in previous studies using this task when a baseline subtraction was not applied (Banaschewski et al. 2004; McLoughlin et al. 2010, 2011; Albrecht et al. 2013; Doehnert et al. 2013), this discrepancy is likely not due to the use of baseline correction. Possible explanations for the lack of ADHD-control difference in the Cue-P3 in this sample are discussed in the main text (see Discussion section).
**SUPPLEMENTARY TABLES**

**Supplementary table 1** Mean (SD) number of artefact-free segments in each ERP average by group and condition during the CPT-OX.

<table>
<thead>
<tr>
<th></th>
<th>ADHD (n=20)*</th>
<th>BD (n=20)</th>
<th>Controls (n=20)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>mean (SD)</td>
<td>mean (SD)</td>
<td>mean (SD)</td>
</tr>
<tr>
<td><strong>Cue</strong></td>
<td>58.35 (11.65)</td>
<td>60.10 (10.28)</td>
<td>60.80 (9.05)</td>
</tr>
<tr>
<td><strong>NoGo</strong></td>
<td>30.75 (3.78)</td>
<td>30.05 (4.73)</td>
<td>30.30 (3.85)</td>
</tr>
<tr>
<td><strong>Go</strong></td>
<td>29.22 (5.99)</td>
<td>29.20 (5.29)</td>
<td>30.65 (4.87)</td>
</tr>
</tbody>
</table>

Abbreviations: ADHD, attention deficit hyperactivity disorder; BD, bipolar disorder.

*Only 18 ADHD participants were included in the average of the Go condition, as two subjects did not have at least 20 artefact-free segments.
**Supplementary table 2** ERP measures from the CPT-OX (without baseline correction): means (SDs), effect sizes (Cohen’s d) and significance of group comparisons.

<table>
<thead>
<tr>
<th></th>
<th>ADHD (n=20)*</th>
<th>BD (n=20)</th>
<th>Controls (n=20)</th>
<th>ADHD vs. BD</th>
<th>ADHD vs. Controls</th>
<th>BD vs. Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>mean (SD)</td>
<td>mean (SD)</td>
<td>mean (SD)</td>
<td>effect size (d)</td>
<td>effect size (d)</td>
<td>effect size (d)</td>
</tr>
<tr>
<td><strong>Cue-P3 at Pz</strong></td>
<td>1.73 (1.37)</td>
<td>0.72 (1.41)</td>
<td>1.47 (1.67)</td>
<td><strong>0.75</strong>*</td>
<td>0.18</td>
<td>0.50</td>
</tr>
<tr>
<td><strong>CNV at Cz</strong></td>
<td>-2.33 (1.02)</td>
<td>-2.79 (1.29)</td>
<td>-3.50 (1.74)</td>
<td>0.41</td>
<td><strong>0.85</strong>*</td>
<td><strong>0.48</strong>*</td>
</tr>
<tr>
<td><strong>NoGo-N2 at Fz</strong></td>
<td>-0.45 (0.96)</td>
<td>0.90 (1.94)</td>
<td>-0.64 (1.88)</td>
<td><strong>0.90</strong>*</td>
<td>0.13</td>
<td><strong>0.83</strong>*</td>
</tr>
<tr>
<td><strong>NoGo-P3 at Cz</strong></td>
<td>3.33 (1.92)</td>
<td>2.93 (2.34)</td>
<td>4.50 (1.69)</td>
<td>0.19</td>
<td><strong>0.67</strong>*</td>
<td><strong>0.79</strong>*</td>
</tr>
<tr>
<td><strong>Go-P3 at CPz</strong></td>
<td>2.77 (2.76)</td>
<td>3.20 (2.85)</td>
<td>3.63 (2.11)</td>
<td>0.17</td>
<td>0.41</td>
<td>0.18</td>
</tr>
</tbody>
</table>

Note: mean and SD were calculated on raw data. Large effect sizes are given in bold, medium effect sizes are given in italics; *p<0.05, †p<0.10; results changing compared to analysis of data with baseline correction are underlined.

Abbreviations: ADHD, attention deficit hyperactivity disorder; BD, bipolar disorder; CNV, contingent negative variation.

*Only 18 participants with ADHD were included in the average of the Go condition, as two participants did not have at least 20 artefact-free segments.
Dear Prof Pariante,

Re: ‘Disorder-specific and shared neurophysiological impairments of attention and inhibition in women with ADHD and women with bipolar disorder’, PSM-D-15-00187

Thank you very much for the insightful reviews of our manuscript ‘Disorder-specific and shared neurophysiological impairments of attention and inhibition in women with ADHD and women with bipolar disorder’. My co-authors and I are delighted to have the opportunity to submit a revised version of our manuscript, which we believe has been improved as a result of the review process. We have detailed below how our revisions address each of the concerns raised by the reviewer.

Reviewer #1

“This is an extremely well conducted and clearly described study. The findings are of interest in that they show both shared and disorder-specific ERP differences in ADHD and bipolar disorder compared to controls.”

Response: We thank the reviewer for the positive comments.
“There are two major limitations to the data in my opinion. Firstly, there is the issue of differences in medication which is covered in the discussion.”

Response: We agree that this is a limitation of our study (as we indeed also commented in the Discussion of the original version of this manuscript, p. 18), but it was an unavoidable one given the inclusion of participants with diagnosed bipolar disorder (BD) who are receiving treatment. In line with previous studies focusing on individuals diagnosed with BD (e.g. Chun et al. 2013; Ethridge et al. 2012), for ethical reasons we could not ask them to come off their antidepressant, antipsychotic or mood-stabilising medications, whereas participants with attention-deficit/hyperactivity disorder (ADHD) could safely come off their stimulant medication for the cognitive-EEG testing. It was not possible to test for the effect of different medications on our cognitive-EEG measures in statistical analyses because limited number of participants would have been included into each sub-group divided by medication. As we explain in the Discussion (see below), despite the possibility that medication could potentially have attenuated some case-control differences, we found significant case-control differences for both BD and ADHD groups.

We nonetheless thank the reviewer for the opportunity to further comment on this issue and better highlight this limitation. We have now expanded the relevant Discussion section, where the revised version reads as follows (pp. 18, second paragraph):

“Firstly, although the groups were matched on gender, age and IQ, there were differences in the prescribed medications that participants with ADHD or BD were taking. While we asked participants with ADHD to stop taking stimulant medications 48 hours prior to the assessment, it was not possible, for ethical reasons, to ask participants to stop mood-stabilising, anti-psychotic or antidepressant medications. Given limited numbers in medication sub-groups, we were not able to directly test the effect of medication on ERP measures, which represents a limitation of the current study. The effects of medication are
difficult to control for in cross-disorder comparison studies where different treatments may be prescribed to different groups of psychiatric patients. Although the understanding of the effects of medications on ERPs is still limited, previous studies suggest that medications may normalise ERPs measures (Anderer et al. 2002; Karaaslan et al. 2003; Galletly et al. 2005). As such, in this study, a medication effect could potentially have resulted in ERPs comparable to controls. Yet, both clinical groups, although some participants were medicated, showed reduced ERP measures compared to controls. Therefore, although the effect of medication represents a potential confounder of this study and may have attenuated some case-control differences, we report impairments in both clinical groups which may not have been produced by the effect of medication. Future studies on samples including non-medicated individuals or a higher number of individuals in each medication sub-group are needed to clarify whether our results may have been affected by medication effects.”

“Secondly there is a concern over the robustness of the diagnoses. This is not adequately addressed. Subjects were only retrospectively diagnosed on the basis of their case notes. Why was there not a diagnostic assessment made when they attended for testing? The biggest concern is that patients with BD may have had undiagnosed ADHD. Such patients may not have had sufficient information in their case notes to confirm or refute such a possibility. This should be commented on.”

Response: We thank the reviewer for this comment, and we take the opportunity to clarify this issue. Participants with ADHD and BD were recruited through specialist National Health Service (NHS) clinics were they received a diagnosis from psychiatric consultants. Eligibility to participate was ascertained by checking these medical records for details of diagnosis and psychiatric history. Fifty-seven people with ADHD, 75 people with BD, and 120 controls fulfilled the inclusion criteria in the study. These included requirements of age, gender and clinical diagnosis based upon DSM-IV criteria. Those with a reported diagnosed comorbidity
of both ADHD and BD at screening were excluded. Recruitment continued until 20 participants were recruited for each group.

Clinical diagnoses and no comorbidity of ADHD and BD were also confirmed through clinical interviews when the participants visited our research centre for the cognitive-EEG assessment. Interviews were conducted by an experienced researcher (GLK), trained by a consultant psychiatrist (PA) with experience of both ADHD and BD. The clinical assessment included the Diagnostic Interview for ADHD in Adults (DIVA) (Kooij & Francken, 2007) and the Barkley Adult ADHD Rating Scale (BAARS-IV) (Barkley and Murphy, 2006) to assess ADHD symptoms; the Beck’s Depression Inventory II (DI) (Beck et al. 1996) as a self-rated measure of depression symptoms; the self-report Altman Self-Rating Mania Scale (ASRM) (Altman et al. 1997) and the Young Mania Rating Scale (YMRS) (Young et al. 1978) to measure mania symptoms. Through this clinical evaluation we were able to further ascertain the lack of comorbid BD in individuals with ADHD and of ADHD in individuals with BD. A full account of recruitment criteria and clinical characteristics of this sample is provided in another paper on this sample currently under review in the Journal of Affective Disorders (Kitsune et al. under review).

Considering the cognitive-electrophysiological focus of the current study, detailed clinical information were not reported in the original version of this manuscript. However, we appreciate that the lack of such information may not allow a full understanding of the recruitment and diagnostic procedures. We have therefore expanded the Sample section of the Methods of our manuscript (pp. 7-8) so that the revised version reads as follows:

“Diagnosis in the clinical groups was confirmed by checking medical records for details of diagnosis and psychiatric history, following DSM-IV criteria (APA, 2000). All of the ADHD participants had a current combined-type diagnosis or a current inattentive-type diagnosis with sufficient symptoms of hyperactivity-impulsivity in childhood to meet a childhood combined-type diagnosis. Participants in the BD group had a diagnosis of BD Type I, having
experienced at least one manic episode in the past. Those who were currently experiencing a manic episode were excluded; all participants included in the BD group were currently euthymic. [...] Individuals with ADHD and individuals with BD with a reported comorbidity of both ADHD and BD were also excluded. Control participants, who reported a history of psychiatric disorders or who were taking psychiatric medication, were excluded from the study. Comorbidity in the clinical groups and lack of psychiatric disorders in the control group were further assessed through clinical evaluations when participants underwent the cognitive-EEG assessment for this study. Further details on the clinical assessment of this sample can be found elsewhere (Kitsune et al. under review). In brief, ADHD was excluded in the BD group after conducting the Diagnostic Interview for Adult ADHD (DIVA v. 2.0; Kooij & Francken, 2007). BD was excluded in the ADHD group by checking for a history of past episodes of depression or hypomania/mania and evaluating current mood symptoms using the Altman Self-Rating Mania Scale (Altman et al. 1997) and the Becks Depression Inventory (Beck et al. 1996), and current and lifetime ever symptoms using the Young Mania Rating Scale (Young et al. 1978). The ADHD and BD groups did not differ significantly on any of the mood scales for current symptoms (Kitsune et al. under review)."

“A definition of euthymia also should be given.”

Response: We thank the reviewer for this comment. All participants in the BD group had a diagnosis of BD Type I, having experienced at least one manic episode in the past, but were currently euthymic, as were not experiencing an episode at the time of the assessment, as ascertained during the clinical evaluation. We agree that this should be better specified in the manuscript, and have therefore added the following sentence to the Sample section of the Methods of our manuscript (p. 7, second paragraph):

“Participants in the BD group had a diagnosis of BD Type I, having experienced at least one manic episode in the past. Those who were currently experiencing a manic episode were excluded; all participants included in the BD group were currently euthymic.”
“I also can't find any reference to mood ratings of patients and whether any current symptoms are used in covariate analysis”

Response: We thank the reviewer for this comment. Both groups underwent a clinical evaluation, also including mood ratings. However, in another study from this sample (Kitsune et al. under review) we found that there were no differences in reported mood symptoms between individuals with ADHD and euthymic BD. For this reason we did not think that the inclusion of these symptoms as covariates would have benefitted our analysis. We nonetheless agree that the inclusion of more information on this would improve our manuscript. We have therefore reported more information on mood ratings in the Sample section of the Methods of our manuscript (p. 8, first paragraph), so that the revised version reads as follows:

“In brief, ADHD was excluded in the BD group after conducting the Diagnostic Interview for Adult ADHD (DIVA v. 2.0; Kooij & Francken, 2007). BD was excluded in the ADHD group by checking for a history of past episodes of depression or hypomania/mania and evaluating current mood symptoms using the Altman Self-Rating Mania Scale (Altman et al. 1997) and the Becks Depression Inventory (Beck et al. 1996), and current and lifetime ever symptoms using the Young Mania Rating Scale (Young et al. 1978). The ADHD and BD groups did not differ significantly on any of the mood scales for current symptoms (Kitsune et al. under review).”

As requested, we have also prepared versions of the figures in greyscale, and submitted both black and white and colour versions.
All authors are in agreement with the content of the revised manuscript. This paper has not previously been published or accepted for publication, nor is it under consideration at another journal.

We thank the editor and the reviewer for this opportunity to revise our manuscript. We look forward to hearing from you in due course.

Yours sincerely,

Giorgia Michelini
giorgia.michelini@kcl.ac.uk
REFERENCES

*Biological Psychiatry* **42**, 948-955.


Chun J, Karam ZN, Marzinzik F, Kamali M, O’Donnell L, Tso IF, Manschreck TC, McInnis M, 
Deldin PJ (2013). Can P300 distinguish among schizophrenia, schizoaffective and bipolar I 

Ethridge LE, Hamm JP, Shapiro JR, Summerfelt AT, Keedy SK, Stevens MC, Pearlson G, 
Neural activations during auditory oddball processing discriminating schizophrenia and 

Delineating ADHD and bipolar disorder: A comparison of clinical profiles and emotional 
lability in adult women. *Journal of Affective Disorders*.

Kooij JJS, Francken MH (2007). Diagnostic Interview for ADHD (DIVA) in adults. Downloaded 
via http://www.divacentre.eu.